Background: Obsessive Compulsive Disorder (OCD) is considered as a serious disabling psychiatric disorder, influencing
2-3% of the total general population, with an unknown etiology.
Methods: A comprehensive literature search in electronic databases was performed to investigate treatments targeting inflammation
in patients suffering from OCD.
Results: The recent studies display that inflammation processes and the dysfunction of the immune system are likely to play a role in
the pathophysiology of OCD, indicating that the disturbances in neurotransmitters such as serotonin and dopamine cannot be alone
involved in the development of OCD. Therefore, it seems that medications with antiinflammatory effects have the potential to be
evaluated as a new therapeutic strategy for OCD. However, this issue can be studied closely if OCD etiological factors are thoroughly
understood. The present review study aims at gathering all obtained results concerning new treatments targeting inflammation in OCD
patients. Reviewing the conducted studies shows that the use of agents with anti-inflammatory properties including some NSAIDs,
Minocycline and Atorvastatin could lead to promising and intriguing results in the treatment of OCD. Curcumin, also showed good
efficacy in the reduction of OCD-like behavior when it has been used in an animal model. However, there is still no definitive and
conclusive evidence for any of the medications proposed.
Conclusion: more future studies are needed to investigate antiinflammatory treatment strategies for OCD and its other subtypes such
as Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS), and Pediatric Autoimmune Neuropsychiatric Disorder associated with
Streptococcal infection (PANDAS).